How long can a person with multiple myeloma live?
Mar 22, 2022
Source: Cainiu Health
Dr. Lin Yunfei
Introduction
In patients with multiple myeloma, the natural course of the disease—without treatment—typically ranges from several months to one year. With systematic treatment, however, survival can be extended to an average of 5–10 years. Numerous factors influence the life expectancy of multiple myeloma patients, including disease stage at diagnosis, response to therapy, and psychological factors.
Multiple myeloma is a malignant plasma cell disorder characterized by uncontrolled proliferation of abnormal plasma cells in the bone marrow. This impairs normal hematopoiesis and may lead to multiple osteolytic bone lesions, hypercalcemia, anemia, and renal impairment.
How long can patients with multiple myeloma live?
Without treatment, the median survival for patients with multiple myeloma is typically several months to one year. With systematic, modern therapy, however, median survival can be extended to approximately 5–10 years.
Numerous factors influence patient survival, including disease stage at diagnosis, response to therapy, and psychological status. Generally, earlier diagnosis and prompt initiation of appropriate treatment correlate with better treatment continuity and longer overall survival. Advanced age at diagnosis, presence of cytogenetic abnormalities (e.g., chromosomal deletions or translocations), and specific laboratory parameters—including serum albumin, serum β2-microglobulin, and C-reactive protein levels—also significantly impact prognosis. Therefore, predicting exact survival duration for individual patients with multiple myeloma is not feasible and must be assessed on a case-by-case basis.
Symptomatic management plays a critical role in the treatment of multiple myeloma: Anemic patients may receive red blood cell transfusions or erythropoietin-stimulating agents. Patients with renal failure require treatment of the underlying disease and, when necessary, hemodialysis. Infections are managed with appropriate combination antibiotic therapy. Chemotherapy remains the cornerstone of treatment; commonly used agents include melphalan, doxorubicin, cyclophosphamide, and corticosteroids. Autologous hematopoietic stem cell transplantation is also a potentially curative therapeutic option for eligible patients.
The above provides an overview of survival expectations in multiple myeloma. We hope this information is helpful to you.
